|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARPC3 |
Gene summary for ARPC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARPC3 | Gene ID | 10094 |
| Gene name | actin related protein 2/3 complex subunit 3 | |
| Gene Alias | ARC21 | |
| Cytomap | 12q24.11 | |
| Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | O15145 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10094 | ARPC3 | GSM4909285 | Human | Breast | IDC | 3.69e-09 | 3.86e-01 | 0.21 |
| 10094 | ARPC3 | GSM4909286 | Human | Breast | IDC | 1.86e-09 | -1.19e-01 | 0.1081 |
| 10094 | ARPC3 | GSM4909293 | Human | Breast | IDC | 3.81e-03 | 8.09e-02 | 0.1581 |
| 10094 | ARPC3 | GSM4909294 | Human | Breast | IDC | 2.52e-21 | 3.16e-01 | 0.2022 |
| 10094 | ARPC3 | GSM4909296 | Human | Breast | IDC | 1.79e-13 | 1.99e-01 | 0.1524 |
| 10094 | ARPC3 | GSM4909297 | Human | Breast | IDC | 1.26e-23 | -6.55e-02 | 0.1517 |
| 10094 | ARPC3 | GSM4909304 | Human | Breast | IDC | 1.83e-03 | 2.47e-01 | 0.1636 |
| 10094 | ARPC3 | GSM4909311 | Human | Breast | IDC | 2.86e-46 | -3.05e-01 | 0.1534 |
| 10094 | ARPC3 | GSM4909312 | Human | Breast | IDC | 1.11e-11 | -1.63e-01 | 0.1552 |
| 10094 | ARPC3 | GSM4909313 | Human | Breast | IDC | 4.74e-03 | -2.35e-01 | 0.0391 |
| 10094 | ARPC3 | GSM4909315 | Human | Breast | IDC | 1.73e-30 | 5.21e-01 | 0.21 |
| 10094 | ARPC3 | GSM4909316 | Human | Breast | IDC | 2.39e-14 | 4.86e-01 | 0.21 |
| 10094 | ARPC3 | GSM4909318 | Human | Breast | IDC | 3.12e-11 | 5.67e-01 | 0.2031 |
| 10094 | ARPC3 | GSM4909319 | Human | Breast | IDC | 1.73e-52 | -3.47e-01 | 0.1563 |
| 10094 | ARPC3 | GSM4909320 | Human | Breast | IDC | 3.18e-08 | -3.40e-01 | 0.1575 |
| 10094 | ARPC3 | GSM4909321 | Human | Breast | IDC | 1.81e-14 | -7.21e-02 | 0.1559 |
| 10094 | ARPC3 | brca1 | Human | Breast | Precancer | 6.50e-24 | 5.48e-01 | -0.0338 |
| 10094 | ARPC3 | brca2 | Human | Breast | Precancer | 1.64e-12 | 4.03e-01 | -0.024 |
| 10094 | ARPC3 | brca3 | Human | Breast | Precancer | 1.12e-08 | 3.04e-01 | -0.0263 |
| 10094 | ARPC3 | brca10 | Human | Breast | Precancer | 1.65e-04 | 3.35e-01 | -0.0029 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190290316 | Endometrium | AEH | regulation of supramolecular fiber organization | 83/2100 | 383/18723 | 2.20e-09 | 1.78e-07 | 83 |
| GO:003295616 | Endometrium | AEH | regulation of actin cytoskeleton organization | 77/2100 | 358/18723 | 1.18e-08 | 7.76e-07 | 77 |
| GO:003253510 | Endometrium | AEH | regulation of cellular component size | 78/2100 | 383/18723 | 1.10e-07 | 5.29e-06 | 78 |
| GO:011005316 | Endometrium | AEH | regulation of actin filament organization | 61/2100 | 278/18723 | 1.83e-07 | 8.11e-06 | 61 |
| GO:004325416 | Endometrium | AEH | regulation of protein-containing complex assembly | 83/2100 | 428/18723 | 3.90e-07 | 1.63e-05 | 83 |
| GO:005125816 | Endometrium | AEH | protein polymerization | 62/2100 | 297/18723 | 9.04e-07 | 3.19e-05 | 62 |
| GO:190290516 | Endometrium | AEH | positive regulation of supramolecular fiber organization | 48/2100 | 209/18723 | 9.11e-07 | 3.20e-05 | 48 |
| GO:003133416 | Endometrium | AEH | positive regulation of protein-containing complex assembly | 52/2100 | 237/18723 | 1.43e-06 | 4.60e-05 | 52 |
| GO:003227116 | Endometrium | AEH | regulation of protein polymerization | 50/2100 | 233/18723 | 4.43e-06 | 1.16e-04 | 50 |
| GO:005149514 | Endometrium | AEH | positive regulation of cytoskeleton organization | 47/2100 | 226/18723 | 2.00e-05 | 4.05e-04 | 47 |
| GO:003227315 | Endometrium | AEH | positive regulation of protein polymerization | 32/2100 | 138/18723 | 4.64e-05 | 7.71e-04 | 32 |
| GO:000815410 | Endometrium | AEH | actin polymerization or depolymerization | 44/2100 | 218/18723 | 7.64e-05 | 1.15e-03 | 44 |
| GO:003004110 | Endometrium | AEH | actin filament polymerization | 39/2100 | 191/18723 | 1.47e-04 | 1.96e-03 | 39 |
| GO:003083310 | Endometrium | AEH | regulation of actin filament polymerization | 35/2100 | 172/18723 | 3.36e-04 | 3.73e-03 | 35 |
| GO:000806410 | Endometrium | AEH | regulation of actin polymerization or depolymerization | 37/2100 | 188/18723 | 4.57e-04 | 4.80e-03 | 37 |
| GO:00308329 | Endometrium | AEH | regulation of actin filament length | 37/2100 | 189/18723 | 5.08e-04 | 5.18e-03 | 37 |
| GO:003083810 | Endometrium | AEH | positive regulation of actin filament polymerization | 21/2100 | 99/18723 | 2.87e-03 | 2.05e-02 | 21 |
| GO:00343148 | Endometrium | AEH | Arp2/3 complex-mediated actin nucleation | 10/2100 | 39/18723 | 9.24e-03 | 4.99e-02 | 10 |
| GO:003297017 | Endometrium | EEC | regulation of actin filament-based process | 89/2168 | 397/18723 | 4.76e-10 | 4.76e-08 | 89 |
| GO:000701517 | Endometrium | EEC | actin filament organization | 95/2168 | 442/18723 | 1.31e-09 | 1.09e-07 | 95 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
| hsa0513018 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
| hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
| hsa0453018 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
| hsa0510018 | Breast | Precancer | Bacterial invasion of epithelial cells | 16/684 | 77/8465 | 3.55e-04 | 2.80e-03 | 2.15e-03 | 16 |
| hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
| hsa0513019 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
| hsa0513119 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
| hsa0453019 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
| hsa0510019 | Breast | Precancer | Bacterial invasion of epithelial cells | 16/684 | 77/8465 | 3.55e-04 | 2.80e-03 | 2.15e-03 | 16 |
| hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0453024 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
| hsa0513024 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
| hsa0513124 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
| hsa0510024 | Breast | IDC | Bacterial invasion of epithelial cells | 17/867 | 77/8465 | 1.69e-03 | 1.19e-02 | 8.93e-03 | 17 |
| hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
| hsa0513234 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0453034 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
| hsa0513034 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
| hsa0513134 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARPC3 | SNV | Missense_Mutation | novel | c.217N>A | p.Leu73Ile | p.L73I | O15145 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARPC3 | SNV | Missense_Mutation | novel | c.441N>C | p.Lys147Asn | p.K147N | O15145 | protein_coding | tolerated(0.05) | benign(0.112) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ARPC3 | SNV | Missense_Mutation | novel | c.353N>T | p.Ala118Val | p.A118V | O15145 | protein_coding | tolerated(0.07) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ARPC3 | SNV | Missense_Mutation | novel | c.163N>C | p.Phe55Leu | p.F55L | O15145 | protein_coding | deleterious(0.02) | probably_damaging(0.91) | TCGA-AG-3878-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ARPC3 | SNV | Missense_Mutation | c.197N>T | p.Arg66Met | p.R66M | O15145 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARPC3 | SNV | Missense_Mutation | novel | c.372G>T | p.Gln124His | p.Q124H | O15145 | protein_coding | tolerated(0.14) | benign(0.02) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| ARPC3 | SNV | Missense_Mutation | rs770287826 | c.362N>T | p.Ala121Val | p.A121V | O15145 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| ARPC3 | SNV | Missense_Mutation | rs763570239 | c.7N>A | p.Ala3Thr | p.A3T | O15145 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARPC3 | SNV | Missense_Mutation | rs200224002 | c.290N>T | p.Thr97Met | p.T97M | O15145 | protein_coding | deleterious(0.03) | benign(0.381) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| ARPC3 | SNV | Missense_Mutation | novel | c.202T>G | p.Leu68Val | p.L68V | O15145 | protein_coding | deleterious(0.01) | possibly_damaging(0.764) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |